Latest headlines

Novartis AG News

Q: Why is Novartis AG up or down today?

Novartis AG (NVS) moves on news. The headlines above show what is driving NVS today; cross-check the reaction against its Fear and Greed Index and trading volume.

Q: How often is Novartis AG news updated?

The Novartis AG (NVS) news feed refreshes continuously as new stories are published.

Q: How does Novartis AG news relate to its Fear and Greed Index?

News drives sentiment and sentiment drives price. Read Novartis AG news alongside its Fear and Greed Index to separate noise from a real shift in mood.

The latest Novartis AG (NVS) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these NVS headlines next to the live Novartis AG Fear and Greed Index.

Latest Novartis AG Headlines60

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

fool.com · Jul 9, 2026

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

fool.com · Jul 9, 2026

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

marketbeat.com · Jul 8, 2026

Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon

seekingalpha.com · Jul 7, 2026

Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition

zacks.com · Jul 6, 2026

Novartis to Buy Myricx Bio for Up to $1.5 Billion

wsj.com · Jul 6, 2026

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

reuters.com · Jul 6, 2026

NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population

zacks.com · Jul 2, 2026

3 European Stocks to Carry Investors Through the Back Half of 2026

marketbeat.com · Jul 1, 2026

Novartis Eyes $5 Billion Pluvicto Opportunity

gurufocus.com · Jun 25, 2026

Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis

reuters.com · Jun 24, 2026

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

businesswire.com · Jun 24, 2026

Biotech's Silent Resurgence (5-Year Base Breakout)

zacks.com · Jun 23, 2026

Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study

zacks.com · Jun 15, 2026

Dividend Safety Check: FNDF and International Large-Cap Dividend Income

247wallst.com · Jun 13, 2026

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

globenewswire.com · Jun 12, 2026

Novartis says rare muscle disease drug shows promise in early trial

reuters.com · Jun 11, 2026

Novartis Reports Positive Data for Neuromuscular Disorder Drug

zacks.com · Jun 11, 2026

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

zacks.com · Jun 11, 2026

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

benzinga.com · Jun 11, 2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

etftrends.com · Jun 11, 2026

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

globenewswire.com · Jun 11, 2026

Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines

businesswire.com · Jun 10, 2026

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

globenewswire.com · Jun 8, 2026

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

zacks.com · Jun 5, 2026

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

globenewswire.com · Jun 4, 2026

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

globenewswire.com · Jun 3, 2026

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

fool.com · Jun 2, 2026

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

globenewswire.com · Jun 1, 2026

Experimental Novartis radiopharma drug shows promise in early study

reuters.com · May 31, 2026

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

globenewswire.com · May 31, 2026

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

globenewswire.com · May 26, 2026

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

globenewswire.com · May 21, 2026

3 International ETFs for Investors Looking Beyond U.S. Stocks

fool.com · May 18, 2026

Cancer Stocks That Are Advancing the Future of Oncology Care

zacks.com · May 18, 2026

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

globenewswire.com · May 17, 2026

Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery

forbes.com · May 13, 2026

Implied Volatility Surging for Novartis Stock Options

zacks.com · May 13, 2026

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

globenewswire.com · May 7, 2026

Novartis to cut 220 jobs as it closes German site

reuters.com · May 5, 2026

Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100

gurufocus.com · Apr 30, 2026

Concurrent Investment Advisors LLC Grows Position in Novartis AG $NVS

defenseworld.net · Apr 29, 2026

UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies

cnbc.com · Apr 29, 2026

Novartis: Revenue Lags In Q1, Outlook Unchanged

seekingalpha.com · Apr 28, 2026

Novartis CEO warns of reality of Trump's drug pricing policy

youtube.com · Apr 28, 2026

Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down

zacks.com · Apr 28, 2026

Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

zacks.com · Apr 28, 2026

Novartis shares fall after weak Q1 hit by Entresto competition

invezz.com · Apr 28, 2026

Novartis CEO: We knew these first two quarters would be bumpy

youtube.com · Apr 28, 2026

Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

cnbc.com · Apr 28, 2026

European markets to open higher as Trump considers Iran peace proposal

cnbc.com · Apr 28, 2026

Novartis Q1 profit down on US generic erosion

reuters.com · Apr 28, 2026

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

globenewswire.com · Apr 28, 2026

NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification

zacks.com · Apr 27, 2026

Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs

cnbc.com · Apr 27, 2026

Novartis receives European Commission approval for Rhapsido skin disease drug

reuters.com · Apr 27, 2026

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

globenewswire.com · Apr 27, 2026

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

globenewswire.com · Apr 24, 2026

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

globenewswire.com · Apr 24, 2026

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

globenewswire.com · Apr 24, 2026

Why Is Novartis AG Up or Down Today?

When Novartis AG (NVS) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a NVS move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why Novartis AG is up or down today.

How Novartis AG News Affects the Price

News does not move the Novartis AG (NVS) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the Novartis AG Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in Novartis AG trading volume. That is the chain to watch: headline, sentiment, volume, then the NVS price.

Trade the Novartis AG News With Sentiment

Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch Novartis AG trading volume spike on a big story, check the Novartis AG price history for context, follow the live NVS price, see the Novartis AG price prediction, and read the Novartis AG Fear and Greed Index for mood.

How do you feel about Novartis AG?

Frequently asked questions

Why is Novartis AG up or down today?

Novartis AG (NVS) moves on news, and the headlines above are the fastest way to see what is driving NVS today, from earnings, guidance and analyst moves to the broader market mood. Cross-check the reaction against the live Novartis AG Fear and Greed Index and NVS trading volume.

What is the latest Novartis AG news?

The newest Novartis AG (NVS) headlines are listed above, most recent first, each linking to the original source. We pull the last 60 stories so you can scroll the full recent NVS news cycle in one place.

Where does Novartis AG news come from?

We aggregate Novartis AG (NVS) headlines from financial news wires and refresh them continuously. Each headline links straight to the original source.

How often is Novartis AG news updated?

Continuously. The Novartis AG (NVS) feed refreshes as new stories are published, so the headlines at the top are the freshest available.

How does Novartis AG news relate to its Fear and Greed Index?

News drives sentiment, and sentiment drives price. A run of negative headlines tends to push the Novartis AG Fear and Greed Index toward fear, positive coverage toward greed. Reading them together is how you separate noise from a real shift in mood.

Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.

About CFGI

The per-asset sentiment record.

CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.

Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.